⌕
Palvella Therapeutics · PVLA · Nasdaq
Tenet 34 · Weak
Compare
$144.60−5.17%At closeTenet 34 · Weak
$144.60−7.88 (−5.17%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Palvella Therapeutics (PVLA) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 17.6% in FY22, net margin −128.5%. Worth your attention in FY25: Returns vs FCF (n/m). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼139.3%
−41.7
FY21→FY25CAGR —
Free cash flow ($M)▼130.7%
−25.0
FY21→FY25CAGR —
Diluted EPS▲52.6%
−3.71
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Stock comp vs FCF
−25.6%

of free cash flow goes to stock comp (was 0.0% in FY21). Owner-earnings math treats it as a real cost.

Share count
+0.0%

11.3mn → 11.3mn diluted shares since FY25. Broadly flat, so EPS moves with net income rather than with the share count.

Returns vs FCF
n/m

$0.0M returned vs $−25.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS−22.8R&D−15.8SG&A−38.6Op income−3.1Tax & other−41.7Net income

Margin trend · direction beats level Gross Operating Net
1007550250%FY21FY25

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemFY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
0.00.00.025.931.4——
Cost of revenue
0.00.00.02.82.4——
Gross profit
———23.129.1——
Research & development
22.88.28.850.264.2▲180.2%−22.8%
Selling, general & admin
15.85.93.116.416.7▲165.2%−1.4%
Total operating expenses
38.614.111.966.680.9▲173.9%−16.9%
Operating incomefeeds ROC rank
−38.6−14.1−11.9−43.5−51.8▼173.9%—
Other income, net
−3.1−3.330.610.26.1——
Pretax income
−41.7−17.418.7−33.3−45.7▼139.3%—
Income tax
0.00.00.00.00.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−41.7−17.418.7−33.3−45.7▼139.3%—
Per share
Diluted EPSbuyback-sensitive
−3.71−7.8314.74−29.61−56.69▲52.6%—
Diluted shares (mn)
11.252.231.270.930.81▲405.4%+93.2%
Margins
Gross margin2nd pct in Healthcare
———89.3%92.5%——
Operating margin
———−167.8%−165.0%——
Net margin22nd pct in Healthcare
———−128.5%−145.6%——
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-31 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.